ESTARYLLA

Post-LOE

norgestimate and ethinyl estradiol

Ichnos Glenmark Innovation

ANDAORAL-28TABLET

Approved

Jan 2013

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

ESTARYLLA (norgestimate and ethinyl estradiol) by Ichnos Glenmark Innovation is ovulation. Approved for pregnancy, pregnancy [see ]. First approved in 2013.

Drug data last refreshed 21h ago

$0.0BPart D

Mechanism of Action

ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Indications (1)

pregnancy

Company

Worked on ESTARYLLA at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.